4//SEC Filing
Landis John B. 4
Accession 0001562180-25-000227
CIK 0001314102other
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 4:04 PM ET
Size
9.3 KB
Accession
0001562180-25-000227
Insider Transaction Report
Form 4
Landis John B.
Director
Transactions
- Exercise/Conversion
Common Stock
2025-01-05+10,000→ 21,400 total - Exercise/Conversion
Restricted Stock Units
2025-01-05−10,000→ 0 totalExercise: $0.00→ Common Stock (10,000 underlying) - Award
Stock Option (Right to Buy)
2025-01-03+40,000→ 40,000 totalExercise: $8.26From: 2026-01-03Exp: 2035-01-03→ Common Stock (40,000 underlying)
Footnotes (1)
- [F1]Fully vested on the one-year anniversary of the grant date.
Documents
Issuer
EyePoint Pharmaceuticals, Inc.
CIK 0001314102
Entity typeother
Related Parties
1- filerCIK 0001477283
Filing Metadata
- Form type
- 4
- Filed
- Jan 6, 7:00 PM ET
- Accepted
- Jan 7, 4:04 PM ET
- Size
- 9.3 KB